Advertisement
UK markets closed
  • FTSE 100

    8,193.49
    -10.44 (-0.13%)
     
  • FTSE 250

    20,798.32
    +11.67 (+0.06%)
     
  • AIM

    774.49
    +0.10 (+0.01%)
     
  • GBP/EUR

    1.1837
    +0.0018 (+0.15%)
     
  • GBP/USD

    1.2826
    +0.0013 (+0.10%)
     
  • Bitcoin GBP

    43,503.40
    -837.19 (-1.89%)
     
  • CMC Crypto 200

    1,204.96
    +38.84 (+3.33%)
     
  • S&P 500

    5,570.07
    +2.88 (+0.05%)
     
  • DOW

    39,313.38
    -62.49 (-0.16%)
     
  • CRUDE OIL

    82.36
    -0.80 (-0.96%)
     
  • GOLD FUTURES

    2,361.10
    -36.60 (-1.53%)
     
  • NIKKEI 225

    40,780.70
    -131.67 (-0.32%)
     
  • HANG SENG

    17,524.06
    -275.55 (-1.55%)
     
  • DAX

    18,472.05
    -3.40 (-0.02%)
     
  • CAC 40

    7,627.45
    -48.17 (-0.63%)
     

Valeo Pharma Second Quarter 2024 Earnings: Misses Expectations

Valeo Pharma (TSE:VPH) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CA$14.1m (up 4.2% from 2Q 2023).

  • Net loss: CA$7.81m (loss widened by 21% from 2Q 2023).

  • CA$0.079 loss per share (further deteriorated from CA$0.077 loss in 2Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Valeo Pharma Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 8.8%. Earnings per share (EPS) also missed analyst estimates by 60%.

Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada.

ADVERTISEMENT

Performance of the Canadian Pharmaceuticals industry.

The company's shares are up 38% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 6 warning signs for Valeo Pharma (4 are a bit unpleasant) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com